{
  "id": "b06ef29df181de3b",
  "title": "Johnson & Johnson Myeloma Approval And What It May Mean For JNJ Stock",
  "description": "Johnson & Johnson (NYSE:JNJ) received FDA approval for DARZALEX FASPRO in combination with D-VRd. The regimen is approved for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This decision expands treatment options for a specific group of multiple myeloma patients. For Johnson & Johnson, this approval sits at the center of its pharmaceutical business, which includes a range of oncology therapies. Multiple myeloma remains a complex...",
  "content": "Oops, something went wrong\n\n[Skip to navigation](https://finance.yahoo.com/news/johnson-johnson-myeloma-approval-may-050700975.html#ybar-navigation) [Skip to main content](https://finance.yahoo.com/news/johnson-johnson-myeloma-approval-may-050700975.html#nimbus-app) [Skip to right column](https://finance.yahoo.com/news/johnson-johnson-myeloma-approval-may-050700975.html#right-rail)\n\n[![](https://s.yimg.com/cv/apiv2/default/20260122/polymarket-logo-white.svg)\\\\\n\\\\\n**Prediction markets are now on Yahoo Finance**\\\\\n\\\\\nGo to hub](https://finance.yahoo.com/markets/prediction/trending/?ncid=100003406)\n\n[![Simply Wall St.](https://s.yimg.com/ny/api/res/1.2/HkW.of1x4JHpvrHVFxKcTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwODtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2021-03/7d6207c0-7d34-11eb-bbee-858baefb8682)](https://simplywall.st/ \"Simply Wall St.\")\n\n# Johnson & Johnson\u2019s Myeloma Approval And What It May Mean For JNJ Stock\n\nSimply Wall St\n\nSun, February 1, 2026 at 12:07 AM EST2 min read\n\n[JNJ \\\\\n-0.02%](https://finance.yahoo.com/quote/JNJ/ \"JNJ\")\n\n[Never miss an important update on your stock portfolio](https://simplywall.st/features/portfolio?utm_medium=finance_user&utm_campaign=updates_head_cta&utm_source=yahoo&blueprint=4388035) and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.\n\n- Johnson & Johnson (NYSE:JNJ) received FDA approval for DARZALEX FASPRO in combination with D-VRd.\n\n- The regimen is approved for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.\n\n- This decision expands treatment options for a specific group of multiple myeloma patients.\n\n\nFor Johnson & Johnson, this approval sits at the center of its pharmaceutical business, which includes a range of oncology therapies. Multiple myeloma remains a complex blood cancer, and drug combinations are an important focus across the sector as companies work to refine standards of car",
  "source": "finance.yahoo.com",
  "source_url": "https://finance.yahoo.com/news/johnson-johnson-myeloma-approval-may-050700975.html",
  "published_at": "20260201T054500Z",
  "fetched_at": "2026-02-02T00:29:20.107852+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United States",
  "raw_data": {
    "url": "https://finance.yahoo.com/news/johnson-johnson-myeloma-approval-may-050700975.html",
    "url_mobile": "",
    "title": "Johnson & Johnson Myeloma Approval And What It May Mean For JNJ Stock",
    "seendate": "20260201T054500Z",
    "socialimage": "https://s.yimg.com/os/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7",
    "domain": "finance.yahoo.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}